Anti-CHRNA1/ACHRA Antibody, clone 2G22 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2G22 is a ZooMAb^® recombinant rabbit monoclonal antibody that detects CHRNA1. It targets an epitope within 20 amino acids from the N-terminal region.

KLH-conjugated linear peptide corresponding to 20 amino acids from the N-terminal region of human CHRNA1/ACHRA.

Quality Control Testing

Evaluated by Western Blotting in SW480 cell lysate.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected CHRNA1/ACHRA in SW480 cell lysate.

Tested Applications

Immunofluorescence Analysis: A 1:100 dilution from a representative lot detected CHRNA1/ACHRA in human skeletal muscle tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CHRNA1/ACHRA in C2C12 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CHRNA1/ACHRA in human and rat skeletal muscle tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound CHRNA1/ACHRA peptide with at least ten thousand-fold (10,000X) higher than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Acetylcholine receptor subunit alpha (UniProt: P027085; also known as ) is encoded by the CHRNA1 (also known as ACHRA, CHNRA) gene (Gene ID: 1134) in human. The acetylcholine receptor subunit alpha (CHRNA1) is a component of the nicotinic acetylcholine receptors (nAChRs), which are pentameric ion channels. Each subunit of the receptor, including the alpha subunit, spans the membrane multiple times and consists of a large extracellular domain, which includes the acetylcholine binding site, and four transmembrane domains (M1-M4) with both the N- and C-termini located extracellularly. The M2 segment lines the pore of the channel and is pivotal in ion selectivity and gating mechanisms. CHRNA1 primarily functions as a part of the muscle-type nAChRs at neuromuscular junctions. These receptors are responsible for mediating synaptic transmission between motor nerve axons and muscle fibers, facilitating muscle contraction. Upon binding of acetylcholine, the receptor undergoes a conformational change that opens its central pore, allowing the flow of cations, particularly Na+ and Ca2+, into the muscle cell, leading to depolarization and subsequent muscle contraction. CHRNA1 is predominantly expressed in skeletal muscle tissues. Its expression is critical during embryonic development for the formation of neuromuscular junctions and is maintained in adult skeletal muscles to regulate muscle contraction. In muscle cells, CHRNA1 is localized to the postsynaptic membrane of the neuromuscular junction. Mutations in the CHRNA1 gene are linked to several neuromuscular disorders, most notably congenital myasthenic syndromes. These are a group of inherited neuromuscular conditions characterized by muscle weakness and fatigue, resulting from defects in neuromuscular transmission. Other potential diseases linked to CHRNA1 dysfunction include autoimmune disorders such as myasthenia gravis, where antibodies target and damage the acetylcholine receptors, leading to similar symptoms of muscle weakness. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.